TNSN97075A1 - Complexes d'inclusion de sels aryl-heterocycliques - Google Patents
Complexes d'inclusion de sels aryl-heterocycliquesInfo
- Publication number
- TNSN97075A1 TNSN97075A1 TNTNSN97075A TNSN97075A TNSN97075A1 TN SN97075 A1 TNSN97075 A1 TN SN97075A1 TN TNSN97075 A TNTNSN97075 A TN TNSN97075A TN SN97075 A TNSN97075 A TN SN97075A TN SN97075 A1 TNSN97075 A1 TN SN97075A1
- Authority
- TN
- Tunisia
- Prior art keywords
- aryl
- inclusion complexes
- heterocyclic salt
- salt inclusion
- heterocyclic
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229920000858 Cyclodextrin Polymers 0.000 abstract 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 abstract 1
- -1 ZIPRASIDONE Chemical class 0.000 abstract 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940097362 cyclodextrins Drugs 0.000 abstract 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 abstract 1
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 abstract 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 1
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 abstract 1
- 229960000607 ziprasidone Drugs 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Machine Translation (AREA)
- Seasonings (AREA)
- Soil Conditioners And Soil-Stabilizing Materials (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSITIONS COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UN COMPOSE ARYLHETEROCYCLIQUE, TEL QUE LA ZIPRASIDONE, DANS UNE CYCLODEXTRINE. LES CYCLODEXTRINES PREFEREES CONSISTENT EN SBECD ET HPBCD ET LES SELS PREFEREES COMPRENNENT LE MESYLATE, L'ESYLATE, LE BESYLATE, LE TARTRATE, LE NAPSYLATE ET LE TOSYLATE. APPLICATION : PREPARATION DE COMPOSITIONS PHARMACEUTIQUES A HYDROSOLUBILITE AMELIOREE.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1920496P | 1996-05-07 | 1996-05-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN97075A1 true TNSN97075A1 (fr) | 2005-03-15 |
Family
ID=21791976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN97075A TNSN97075A1 (fr) | 1996-05-07 | 1997-05-06 | Complexes d'inclusion de sels aryl-heterocycliques |
Country Status (47)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| DK0811386T3 (da) * | 1996-05-07 | 2005-01-03 | Pfizer | Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6706721B1 (en) | 1998-04-29 | 2004-03-16 | Osi Pharmaceuticals, Inc. | N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate |
| US20080113025A1 (en) * | 1998-11-02 | 2008-05-15 | Elan Pharma International Limited | Compositions comprising nanoparticulate naproxen and controlled release hydrocodone |
| JP4503724B2 (ja) * | 1999-05-10 | 2010-07-14 | 栄研化学株式会社 | ホタルルシフェリンの安定化方法 |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| US6884885B2 (en) | 2000-12-21 | 2005-04-26 | Cerestar Holding B.V. | Production of cyclodextrin complexes |
| US7034013B2 (en) * | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| EP1269994A3 (fr) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament |
| US20040048876A1 (en) * | 2002-02-20 | 2004-03-11 | Pfizer Inc. | Ziprasidone composition and synthetic controls |
| US6869939B2 (en) * | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| SI1542668T1 (sl) * | 2002-08-20 | 2009-08-31 | Bristol Myers Squibb Co | Aripiprazol sestavljena formulacija in postopek |
| PL375981A1 (en) * | 2002-09-17 | 2005-12-12 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| BR0315568A (pt) * | 2002-10-25 | 2005-08-23 | Pfizer Prod Inc | Formulações de depósito injetáveis |
| WO2004037224A1 (fr) * | 2002-10-25 | 2004-05-06 | Pfizer Products Inc. | Formulations de depot d'agents actifs arylheterocycliques sous forme de suspension |
| US20040142039A1 (en) * | 2002-10-31 | 2004-07-22 | Pfizer Inc | Solid and semi-solid polymeric ionic conjugates |
| JP2006506396A (ja) * | 2002-10-31 | 2006-02-23 | ファイザー・プロダクツ・インク | 固体医薬の液体複合体 |
| MXPA03009945A (es) | 2002-11-05 | 2007-04-16 | Lg Electronics Inc | Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido. |
| CN1255105C (zh) * | 2002-12-17 | 2006-05-10 | 上海医药工业研究院 | 齐拉西酮及其盐的水溶性包合物及其制备方法 |
| CA2528100A1 (fr) * | 2003-06-03 | 2005-04-21 | Teva Pharmaceutical Industries Ltd | Formes polymorphes de ziprasidone chlorhydrate et procedes pour leur elaboration |
| EP1663166A2 (fr) * | 2003-09-02 | 2006-06-07 | Imran Ahmed | Formes posologiques a liberation prolongee de ziprasidone |
| JP2007513202A (ja) * | 2003-12-08 | 2007-05-24 | ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティー・オブ・アリゾナ | 相乗的な抗癌組成物 |
| US20050163858A1 (en) * | 2003-12-31 | 2005-07-28 | Garth Boehm | Ziprasidone formulations |
| SI21703A (en) * | 2004-01-14 | 2005-08-31 | Lek Farmacevtska Druzba Dd | Inclusion complexes of perindopril, procedure of their preparation, pharmaceutical compositions containing these complexes and their application in treatment of hypertensia |
| EP1744750A2 (fr) | 2004-05-06 | 2007-01-24 | Sandoz AG | Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree |
| WO2006032957A1 (fr) * | 2004-05-26 | 2006-03-30 | Pfizer Products Inc. | Procédé in vitro predictif |
| EP1753400A4 (fr) * | 2004-06-11 | 2012-11-28 | Reddys Lab Ltd Dr | Forme de dosage de ziprasidone |
| KR20130030305A (ko) * | 2004-11-16 | 2013-03-26 | 엘란 파마 인터내셔널 리미티드 | 주사가능한 나노입자형 올란자핀 제형 |
| EP1863806A1 (fr) * | 2005-02-11 | 2007-12-12 | Teva Pharmaceutical Industries Ltd | Ziprasidone mesylate amorphe |
| EP1855651A4 (fr) * | 2005-03-03 | 2011-06-15 | Elan Pharma Int Ltd | Compositions nanoparticulaires de derives d'amide heterocyclique |
| EP1858892A1 (fr) * | 2005-03-14 | 2007-11-28 | Teva Pharmaceutical Industries Ltd | Mesylate de ziprasidone anhydre et son procede de preparation |
| US20060270684A1 (en) * | 2005-03-14 | 2006-11-30 | Judith Aronhime | Crystalline forms of ziprasidone mesylate |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| US20100204178A1 (en) | 2006-10-02 | 2010-08-12 | James Cloyd | Novel parenteral carbamazepine formulation |
| CN100391458C (zh) * | 2006-02-07 | 2008-06-04 | 上海医药工业研究院 | 齐拉西酮或其盐包合物制备方法 |
| KR20170091770A (ko) | 2006-07-10 | 2017-08-09 | 파이온 유케이 리미티드 | 속효형 벤조디아제핀 염 및 이의 중합체 형태 |
| MX2009011681A (es) * | 2007-05-18 | 2009-11-10 | Scidose Llc | Formulaciones de ziprasidona. |
| US8192721B2 (en) * | 2007-12-13 | 2012-06-05 | Verrow Pharmaceuticals, Inc. | Compositions useful for reducing toxicity associated with gadolinium-based contrast agents |
| CN101314045B (zh) * | 2008-05-09 | 2013-01-23 | 沈阳药科大学 | 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法 |
| US20130108701A1 (en) | 2010-05-25 | 2013-05-02 | Krishna Murthy Bhavanasi | Solid Dosage Forms of Antipsychotics |
| EP2450039A1 (fr) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Régime de dosage permettant la sédation avec CNS 7056 (Remimazolam) |
| SI23610A (sl) | 2011-01-13 | 2012-07-31 | Diagen@d@o@o | Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji |
| CN102793701B (zh) * | 2011-05-25 | 2014-12-17 | 上海医药工业研究院 | 卢拉西酮组合物 |
| TW201332572A (zh) | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| AR094963A1 (es) | 2013-03-04 | 2015-09-09 | Ono Pharmaceutical Co | Reacción de oxidación excelente en el índice de conversión |
| WO2023108156A1 (fr) * | 2021-12-11 | 2023-06-15 | Beloteca, Inc. | Formulations de ziprasidone |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3459731A (en) * | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
| IT1196033B (it) | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| MX173362B (es) | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| IT1255462B (it) | 1992-07-28 | 1995-11-02 | Grazia Maffione | Metodo di preparazione di composti di inclusione di nimesulide con ciclodestrine |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| IT1263831B (it) | 1993-01-29 | 1996-09-04 | Paolo Chiesi | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina |
| HU210922B (en) | 1993-05-24 | 1995-09-28 | Europharmaceuticals Sa | Nimesulide alkali salt cyclodextrin inclusion complexes their preparation and pharmaceutical compositions containing them |
| IT1269578B (it) | 1994-04-22 | 1997-04-08 | Chiesi Farma Spa | Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base. |
| BE1008307A3 (fr) | 1994-06-16 | 1996-04-02 | Europharmaceuticals Sa | Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation. |
| DK0811386T3 (da) | 1996-05-07 | 2005-01-03 | Pfizer | Fremgangsmåde til udvælgelse af et salt til fremstilling af et inklusionskompleks |
| TW491847B (en) | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| UA57734C2 (uk) * | 1996-05-07 | 2003-07-15 | Пфайзер Інк. | Комплекси включення арилгетероциклічних солей |
| IL126590A (en) | 1996-05-07 | 2001-11-25 | Pfizer | Trihydrate salt of -5 (-2 (-4 (1 (2, 2-benzothiazole - 3yl) -1-piperazinyl) ethyl) - 6-chloro-1, 3-dihydro-2 (1H) - indole - 2On (= Ziprasidone) and pharmaceutical preparations containing it |
| JPH10194996A (ja) * | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
-
1997
- 1997-01-04 UA UA98105560A patent/UA57734C2/uk unknown
- 1997-03-25 TW TW086103749A patent/TW514529B/zh not_active IP Right Cessation
- 1997-04-01 CA CA002251912A patent/CA2251912C/fr not_active Expired - Lifetime
- 1997-04-01 AU AU19372/97A patent/AU713711B2/en not_active Expired
- 1997-04-01 US US09/147,239 patent/US6232304B1/en not_active Expired - Lifetime
- 1997-04-01 ME MEP-1997-172A patent/ME00880B/me unknown
- 1997-04-01 TR TR1998/02231T patent/TR199802231T2/xx unknown
- 1997-04-01 SK SK1504-98A patent/SK282032B6/sk not_active IP Right Cessation
- 1997-04-01 HU HU9902799A patent/HU222451B1/hu active IP Right Grant
- 1997-04-01 CZ CZ0346198A patent/CZ297847B6/cs not_active IP Right Cessation
- 1997-04-01 KR KR1019980708959A patent/KR20000010823A/ko active Search and Examination
- 1997-04-01 JP JP53966997A patent/JP3579060B2/ja not_active Expired - Lifetime
- 1997-04-01 IL IL12654697A patent/IL126546A/xx not_active IP Right Cessation
- 1997-04-01 DE DE1997627218 patent/DE69727218T2/de not_active Expired - Lifetime
- 1997-04-01 WO PCT/IB1997/000321 patent/WO1997041896A2/fr active IP Right Grant
- 1997-04-01 PL PL97329928A patent/PL189324B1/pl unknown
- 1997-04-01 SI SI9730623T patent/SI0900088T1/xx unknown
- 1997-04-01 ES ES97907246T patent/ES2212809T3/es not_active Expired - Lifetime
- 1997-04-01 NZ NZ332220A patent/NZ332220A/xx not_active IP Right Cessation
- 1997-04-01 PT PT97907246T patent/PT900088E/pt unknown
- 1997-04-01 DK DK97907246T patent/DK0900088T3/da active
- 1997-04-01 BR BR9709213A patent/BR9709213A/pt not_active Application Discontinuation
- 1997-04-01 EP EP97907246A patent/EP0900088B1/fr not_active Expired - Lifetime
- 1997-04-01 AT AT97907246T patent/ATE257714T1/de active
- 1997-04-01 CN CN97194242A patent/CN1216923A/zh active Pending
- 1997-04-01 EA EA199800910A patent/EA001731B1/ru not_active IP Right Cessation
- 1997-04-02 HN HN1997000039A patent/HN1997000039A/es unknown
- 1997-04-10 GT GT199700044A patent/GT199700044A/es unknown
- 1997-04-28 CO CO97022511A patent/CO4600677A1/es unknown
- 1997-04-30 AP APAP/P/1997/000977A patent/AP796A/en active
- 1997-05-04 EG EG37897A patent/EG24135A/xx active
- 1997-05-05 AR ARP970101854A patent/AR007002A1/es active IP Right Grant
- 1997-05-05 ID IDP971488A patent/ID16866A/id unknown
- 1997-05-06 UY UY24544A patent/UY24544A1/es not_active IP Right Cessation
- 1997-05-06 MY MYPI97001984A patent/MY121999A/en unknown
- 1997-05-06 RS YU17297A patent/RS49532B/sr unknown
- 1997-05-06 ZA ZA973874A patent/ZA973874B/xx unknown
- 1997-05-06 MA MA24596A patent/MA24172A1/fr unknown
- 1997-05-06 DZ DZ970067A patent/DZ2220A1/fr active
- 1997-05-06 TN TNTNSN97075A patent/TNSN97075A1/fr unknown
- 1997-05-07 HR HR970237A patent/HRP970237B1/xx not_active IP Right Cessation
- 1997-05-12 SA SA97180024A patent/SA97180024B1/ar unknown
-
1998
- 1998-10-27 IS IS4880A patent/IS2524B/is unknown
- 1998-10-30 OA OA9800204A patent/OA10907A/en unknown
- 1998-11-03 BG BG108606A patent/BG64475B2/bg unknown
- 1998-11-03 BG BG102894A patent/BG64474B1/bg unknown
- 1998-11-06 NO NO19985192A patent/NO324373B1/no not_active IP Right Cessation
-
2001
- 2001-05-07 US US09/850,658 patent/US6399777B2/en not_active Expired - Lifetime
-
2004
- 2004-02-25 BG BG108606A patent/BG64475B1/bg unknown
- 2004-08-27 AR ARP040103099A patent/AR045528A2/es not_active Application Discontinuation
-
2006
- 2006-12-13 GE GEAP20069762A patent/GEP20074185B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN97075A1 (fr) | Complexes d'inclusion de sels aryl-heterocycliques | |
| TNSN97023A1 (fr) | Derives de triazole utiles en therapeutique, procedes pour leur preparation et compositions les contenant. | |
| RU94028890A (ru) | Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов | |
| TNSN98090A1 (fr) | Formulations pharmaceutiques contenant du voriconazole, et procede pour leur preparation. | |
| ES2188584T3 (es) | Derivados heterociclicos de amina. | |
| MA26782A1 (fr) | Pyrazolobenzodiazepines en tant qu'inhibiteurs de cdk2. | |
| WO1998038984A3 (fr) | Preparations d'agents pharmaceutiques hydrophobes | |
| TNSN97015A1 (fr) | Nouveaux derives de 19-nor-pregnene. | |
| WO2001092283A3 (fr) | Composes de cobalamine utilises en tant qu'agents cardio-vasculaires et agents d'imagerie | |
| DE69106947D1 (de) | Zyklodextrine enthaltende galenische Zusammensetzungen. | |
| YU72594A (sh) | Vodeni rastvor inkluzionih kompleksa benzotiofen jedinjenja sa vodorastvornim ciklodekstrinima, njegove farmaceutske formulacije i postupci za dobijanje | |
| NO995978L (no) | Reseptorbindende konjugater | |
| EE200200281A (et) | Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks | |
| BE1014502A5 (fr) | Compositions pharmaceutiques. | |
| ATE280588T1 (de) | Dextran-leptin konjugate, pharmazeutische zusammentsetzungen und verbundene verfahren | |
| ATE363920T1 (de) | Hydrophobe iodverbindung enthaltende liposome | |
| BR0015025A (pt) | Solução oral contendo galantamina e um agente adoçante | |
| TNSN97042A1 (fr) | Derives de quinoxaline utiles en therapeutique, procede pour leur preparation et formulations pharmaceutiques les contenant. | |
| ES2180640T3 (es) | Derivados glicosilados solubles en agua de compuestos 1,2-ditiinos. | |
| EP1081140A3 (fr) | Composés de pyrimidine-2,4,6-trione | |
| BR0006838A (pt) | Complexos de paroxetina, com ciclodextrinas ou derivados de ciclodextrinas | |
| NO20021429L (no) | 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner | |
| ECSP972098A (es) | Complejos de inclusion de sales de aril meterociclicos | |
| FR2789078B3 (fr) | Derives d'acide pyrazolecarboxylique, leur preparation, les compositions pharmaceutiques en contenant | |
| ATE243219T1 (de) | 9a, 11b-dehydro derivative von 9-oxime-3-keto-6-0-methylerythromycin |